Effect of vitamin D3 vs. calcifediol on VDR concentration and fiber size in skeletal muscle

Introduction This study sought to examine the effect of vitamin D 3 (VD 3 ) 3200 IU/d, calcifediol (HyD) 20mcg/d, or placebo on intramyonuclear vitamin D receptor (VDR) concentration, muscle fiber cross-sectional area (FCSA), and muscle satellite cell activation. Materials and methods It was conduct...

Full description

Saved in:
Bibliographic Details
Published in:Journal of bone and mineral metabolism 2023, Vol.41 (1), p.41-51
Main Authors: Ceglia, Lisa, Rivas, Donato A., Schlögl, Mathias, Fielding, Grace B., Egli, Andreas, Bischoff-Ferrari, Heike A., Dawson-Hughes, Bess
Format: Article
Language:English
Subjects:
25-Hydroxyvitamin D
Cell activation
Clinical trials
Immunofluorescence
Medicine
Medicine & Public Health
Metabolic Diseases
Musculoskeletal system
NCT
NCT02527668
Original Article
Orthopedics
Osteopenia
Placebos
Post-menopause
Satellite cells
Skeletal muscle
Vitamin D receptors
Vitamin D3
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction This study sought to examine the effect of vitamin D 3 (VD 3 ) 3200 IU/d, calcifediol (HyD) 20mcg/d, or placebo on intramyonuclear vitamin D receptor (VDR) concentration, muscle fiber cross-sectional area (FCSA), and muscle satellite cell activation. Materials and methods It was conducted on a subset of the VD 3 ( n  = 12), HyD ( n  = 11), and placebo ( n  = 13) groups who participated in the 6-month randomized controlled HyD Osteopenia Study in postmenopausal women. Baseline and 6-month vastus lateralis muscle cross sections were probed for VDR, fiber type I and II, and PAX7 (satellite cell marker) using immunofluorescence. Results Baseline mean ± SD age was 61 ± 4 years and serum 25-hydroxyvitamin D (25OHD) level was 55.1 ± 22.8 nmol/L. Baseline characteristics did not differ significantly by group. Six-month mean ± SD 25OHD levels were 138.7 ± 22.2 nmol/L (VD 3 ), 206.8 ± 68.8 nmol/L (HyD), and 82.7 ± 36.1 nmol/L (placebo), ANOVA P   0.358). Conclusion This study demonstrated no significant change in intramyonuclear VDR in response to either form of vitamin D vs. placebo. Type I FCSA significantly increased with VD 3 , but not with HyD at 6 months. As type I fibers are more fatigue resistant than type II, enlargement in type I suggests potential for improved muscle endurance. Although HyD resulted in the highest 25OHD levels, no skeletal muscle benefits were noted at these high levels. Clinical trial NCT02527668.
ISSN:0914-8779
1435-5604
DOI:10.1007/s00774-022-01374-y